跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

487R-9

SMAD4 (MRQ-72) Rabbit Monoclonal Antibody

For In Vitro Diagnostic Use in Select Regions

别名:

Mothers Against Decapentaplegic Homolog 4 Rabbit Monoclonal Antibody

登录查看公司和协议定价


About This Item

UNSPSC代码:
12352203

生物来源

rabbit

质量水平

抗体产品类型

primary antibodies

克隆

MRQ-72, monoclonal

包装

vial of 0.1 mL concentrate (487R-94)
vial of 0.1 mL concentrate (487R-94-RUO) Research Use Only
vial of 0.5 mL concentrate (487R-(95)
vial of 1.0 mL (concentrate (487R-96))
vial of 1.0 mL concentrate (487R-96-RUO) Research Use Only
vial of 1.0 mL pre-dilute (487R-97-RUO) Research Use Only
vial of 1.0 mL pre-dilute ready-to-use (487R-97)
vial of 7.0 mL pre-dilute ready-to-use (487R-98)
vial of 7.0 mL pre-dilute ready-to-use (487R-98-RUO) Research Use Only

制造商/商品名称

Cell Marque

同位素/亚型

IgG

控制

pancreas

可视化

cytoplasmic, nuclear

一般描述

Mothers Against Decapentaplegic Homolog 4 (SMAD4) is a transcription factor that is involved in TGFβ signalling pathways and acts as a tumor suppressor. SMAD4 is commonly expressed in a variety of cancers, including pancreatic ductal adenocarcinoma (PDA), colorectal carcinoma (CRC), hepatocellular carcinoma (HCC), and gastric carcinomas, as well as non-neoplastic liver, pancreas, and colon. However, a loss of expression has been observed in a subset of PDA, CRC, and gastric carcinomas due to a variety of mutations including nonsense, missense, deletions, and splice site changes. In contrast, SMAD4 is over-expressed in HCC compared to the weak expression that is exhibited in the non-neoplastic liver.

质量

IVD - MQ500

RUO - MQ100

外形

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

制备说明

Download the IFU specific to your product lot and format

Note: This requires a keycode which can be found on your packaging or product label.

其他说明

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

法律信息

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our 产品选型工具.

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Y H Kim et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 15(4), 574-580 (2004-03-23)
Transforming growth factor-beta (TGF-beta) modulates the growth and function of many cells, including those with malignant transformation. Smad proteins have been identified as major components in the intracellular signaling of TGF-beta family members. To clarify the correlations between clinicopathologic profiles
R Salovaara et al.
Gut, 51(1), 56-59 (2002-06-22)
Loss of DNA sequences from chromosome 18q21 is a major genetic change in colorectal tumorigenesis. Multiple genes have been identified in this area. One of these, DPC4 (deleted in pancreatic cancer 4, also known as SMAD4), is mutated in a
K L Woodford-Richens et al.
Proceedings of the National Academy of Sciences of the United States of America, 98(17), 9719-9723 (2001-08-02)
Loss of chromosome 18q21 is well documented in colorectal cancer, and it has been suggested that this loss targets the DCC, DPC4/SMAD4, and SMAD2 genes. Recently, the importance of SMAD4, a downstream regulator in the TGF-beta signaling pathway, in colorectal
Michael Torbenson et al.
Human pathology, 33(9), 871-876 (2002-10-16)
In the normal liver, the transforming growth factor beta (TGF-beta) signaling pathway plays an important role in inhibiting hepatocyte growth. This effect is mediated through Smad4 (or Dpc4), a tumor-suppressor gene that affects gene transcription and controls cell growth. A
Lauren L Ritterhouse et al.
Histopathology, 75(4), 546-551 (2019-05-06)
SMAD4 (DPC4) is a tumour suppressor gene that is dysregulated in various tumour types, particularly pancreaticobiliary and gastrointestinal carcinomas. Corresponding loss of protein expression has been reported in approximately 50% of pancreatic and 25% of colonic adenocarcinomas. In the evaluation

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门